Obesity, diabetes drugs push Novo Nordisk and Eli Lilly to front of pharma's growth pack in Q2

As the coronavirus surged and subsided, several biopharma companies experienced exaggerated revenue spikes and troughs.

These days, as pharma sales have become more stable, the only drugmakers showing significant revenue spurts are those producing next-gen obesity and diabetes treatments. As companies have reported their second-quarter financial results over the last few weeks, gains by Novo Nordisk and Eli Lilly have drawn the most attention.